Development and targeted use of nilotinib in chronic myeloid leukemia

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 233-243

  Fava, Carmen ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CML; Imatinib intolerance; Imatinib resistance; Nilotinib

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ANEMIA; AUTOPHOSPHORYLATION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERANCE; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRURITUS; QT PROLONGATION; RASH; REVIEW; SINGLE DRUG DOSE; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 77953653399     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Aichberger KJ, Mayerhofer M, Krauth MT, et al. 2005. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res, 65:9436-9444 (Pubitemid 41508012)
2. Azam M, Latek RR, Daley GQ. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell, 112:831-843 (Pubitemid 36378885)
3. Barnes DJ, Melo JV. 2002. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol, 108:180-202. (Pubitemid 35356695)
4. Bhatia R, Holtz M, Niu N, et al. 2003. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101:4701-4707 (Pubitemid 36857723)
5. Bradeen HA, Eide CA, O'Hare T, et al. 2006. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 108:2332-2338 (Pubitemid 44497517)
6. Brendel C, Scharenberg C, Dohse M, et al. 2007. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia, 21:1267-1275 (Pubitemid 46831816)
7. Buchdunger E, Cioffi CL, Law N, et al. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 295:139-145
8. Chan LC, Karhi KK, Rayter SI, et al. 1987. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature, 325:635-637 (Pubitemid 17055688)
9. Corbin AS, Buchdunger E, Pascal F, et al. 2002. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem, 277:32214-32219 (Pubitemid 34969036)
10. Cortes J, Jabbour E, Kantarjian H, et al. 2007. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 110:4005-4011 (Pubitemid 350248456)
11. Cortes JE, O'Brien SM, Ferrajoli A, et al. 2008. 50. Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP). J Clin Oncol, 26(May 20 Suppl): Abstr 7016.
12. Dai Y, Rahmani M, Corey SJ, et al. 2004. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem, 279:34227-34239 (Pubitemid 39318046)
13. Deininger M, Buchdunger E, Druker BJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105:2640-2653 (Pubitemid 40446252)
14. Donato NJ, Wu JY, Stapley J, et al. 2003. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101:690-698 (Pubitemid 36077594)
15. Druker BJ, Guilhot F, O'Brien SG, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355:2408-2417 (Pubitemid 44903745)
16. Faderl S, Talpaz M, Estrov Z, et al. 1999. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med, 131:207-219 (Pubitemid 29365004)
17. Fiskus W, Pranpat M, Bali P, et al. 2006. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood, 108:645-652 (Pubitemid 44061366)
18. Giles FJ, Larson RA, Kantarjian HM, et al. 2008. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. J Clin Oncol, 26(May 20 Suppl):Abstr 7017.
19. Goldman JM, Hughes T, Radich J, et al. 2005. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS Study. Blood, 106:Abstract 163.
20. Goldman JM, Melo JV. 2003. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med, 349:1451-1464
21. Golemovic M, Verstovsek S, Giles F, et al. 2005. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res, 11:4941-4947 (Pubitemid 41557215)
22. Griffin JD, Weisberg EL. 2005. Simultaneous administration of AMN107 and imatinib in the treatment of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia. Blood, (ASH Annual Meeting Abstracts), 106:694.
23. Hochhaus A, Hughes T. 2004. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am, 18:641-56, ix. (Pubitemid 38969136)
24. Hochhaus A, Kreil S, Corbin AS, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16:2190-2196 (Pubitemid 35331833)
25. Hu Y, Liu Y, Pelletier S, et al. 2004. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet, 36:453-461 (Pubitemid 38620028)
26. Hughes T, Deininger M, Hochhaus A, et al. 2006. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108:28-37. (Pubitemid 43990609)
27. Jabbour E, Cortes J, Kantarjian H. 2007. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs, 16:679-7. Erratum in: Expert Opin Investig Drugs, 2007;16:1135.
28. Jabbour E, Hochhaus A, le Coutre P, et al. 2008. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). J Clin Oncol, 26(May 20 Suppl):Abstr 7063.
29. Jabbour E, Kantarjian H, Jones D, et al. 2006. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia, 20:1767-1773 (Pubitemid 44574988)
30. Jabbour E, Kantarjian H, Jones D, et al. 2007. Event-free survival in patients (pts) with chronic myeloid leukemia (CML) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure is dependent on the in vitro sensitivity of BCR-ABL kinase domain (KD) mutations. Blood, (ASH Annual Meeting Abstracts) 110:1941.
31. Jabbour E, Kantarjian H, Jones D, et al. 2007. In vivo response to sequential tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) modeled based on in vitro properties of particular BCR-ABL kinase domain (KD) mutations. Blood, (ASH Annual Meeting Abstracts) 110:1947.
32. Jabbour E, Kantarjian H, Jones D, et al. 2008. Clinical characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood, Sep 25. [Epub ahead of print].
33. Jorgensen HG, Allan EK, Jordanides NE, et al. 2007. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109:4016-4019
34. Kantarjian H, Giles F, Wunderle L, et al. 2006. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354:2542-2551 (Pubitemid 43882350)
35. Kantarjian HM, Giles FJ, A. Hochhaus, et al. 2008. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. J Clin Oncol, 26(May 20 Suppl):Abstr 7010.
36. Kantarjian HM, O'Brien S, Cortes J, et al. 2003. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer, 98:2636-2642 (Pubitemid 37509527)
37. Koptyra M, Falinski R, Nowicki MO, et al. 2006. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 108:319-327 (Pubitemid 43990645)
38. le Coutre P, Giles FJ, Apperley J, et al. 2008. Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study. J Clin Oncol, 26(May 20 Suppl):Abstr 7050.
39. Lionberger JM, Wilson MB, Smithgall TE. 2000. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem, 275:18581-18585
40. Litzow MR. 2006. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med, 130:669-679
41. Mahon F-X, Lagarde V, Manley PW, et al. 2004. Generation of resistance cell lines to AMN107, a new inhibitor of BCR-ABL and its effects on cell lines sensitive and resistant to imatinib. Blood, (ASH Annual Meeting Abstracts) 104:4670.
42. Manley PW, Cowan-Jacob SW, Fendrich G, et al. 2005. Molecular interactions between the highly selective pan-Bcr-Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl. Blood, (ASH Annual Meeting Abstracts) 106:3365.
43. Nagar B, Bornmann WG, Pellicena P, et al. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res, 62:4236-4243 (Pubitemid 34827278)
44. Nicolini FE, Corm S, Le QH, et al. 2006. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia, 20:1061-1066
45. Nilotinib (Tasigna) for CML. 2008. Med Lett Drugs Ther, 50:26-27
46. O'Brien SG, Guilhot F, Larson RA, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348:994-1004. (Pubitemid 36302244)
47. O'Hare T, Eide CA, Deininger MWN. 2007. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 110:2242-2249 (Pubitemid 47523141)
48. O'Hare T, Eide CA, Tyner JW, et al. 2007. SGX70393 Inhibits Bcr-AblT315I in vitro and in vivo and completely suppresses resistance when combined with nilotinib or dasatinib. Blood, (ASH Annual Meeting Abstracts) 110:535.
49. O'Hare T, Eide CA, Tyner JW, et al. 2008. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A, 105:5507-5512 (Pubitemid 351753893)
50. O'Hare T, Walters DK, Stoffregen EP, et al. 2005. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65:4500-4505 (Pubitemid 40740783)
51. Ottmann OG, Larson RA, Kantarjian HM, et al. 2007. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood, (ASH Annual Meeting Abstracts) 110:2815.
52. Picard S, Titier K, Etienne G, et al. 2007. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109:3496-3499 (Pubitemid 46572540)
53. Quintas-Cardama A, Cortes JE. 2006. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc, 81:973-988 (Pubitemid 43993489)
54. Ray A, Cowan-Jacob S, Manley PW, et al. 2007. Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 by a random mutagenesis study. Blood, 109:5011-5015 (Pubitemid 46827801)
55. Ries LAG MD, Krapcho M, et al. 2004. Sourveillance Epidemiology and End Results (SEER) Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, MD, USA. Accessed September 2007. URL: http://seercancergov/csr/1975- 2004
56. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature, 243:290-293
57. Roy L, Guilhot J, Krahnke T, et al. 2006. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 108:1478-1484 (Pubitemid 44316111)
58. Schindler T, Bornmann W, Pellicena P, et al. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289:1938-1942
59. Shah NP, Nicoll JM, Branford S, et al. 2005. Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: rationale for combination tyrosine kinase inhibitor therapy. Blood, (ASH Annual Meeting Abstracts) 106:1093.
60. Shah NP, Nicoll JM, Nagar B, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2:117-125 (Pubitemid 41039112)
61. Shah NP. 2005. Loss of response to imatinib: mechanisms and management. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. pp 183-187
62. Talpaz M, Shah NP, Kantarjian H, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354:2531-2541 (Pubitemid 43882349)
63. Thomas J, Wang L, Clark RE, et al. 2004. Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 104:3739-3745 (Pubitemid 39564452)
64. Verstovsek S, Golemovic M, Kantarjian H, et al. 2005. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer, 104:1230-1236 (Pubitemid 41278958)
65. von Bubnoff N, Manley PW, Mestan J, et al. 2006. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood, 108:1328-1333 (Pubitemid 44232032)
66. von Bubnoff N, Schneller F, Peschel C, et al. 2002. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet, 359:487-491 (Pubitemid 34164296)
67. Weisberg E, Catley L, Wright RD, et al. 2007. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood, 109:2112-2120 (Pubitemid 46348213)
68. Weisberg E, Manley PW, Breitenstein W, et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7:129-141 (Pubitemid 40248339)
69. Wendel HG, de Stanchina E, Cepero E, et al. 2006. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A, 103:7444-7449 (Pubitemid 43727852)
70. White DL, Saunders VA, Dang P, et al. 2006. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108:697-704. (Pubitemid 44061372)